Common Contracts
12 similar Underwriting Agreement contracts by ELI LILLY & Co, Lilly Eli & Co
ELI LILLY AND COMPANY Underwriting AgreementUnderwriting Agreement • August 14th, 2024 • ELI LILLY & Co • Pharmaceutical preparations
ELI LILLY AND COMPANY Underwriting AgreementUnderwriting Agreement • February 9th, 2024 • ELI LILLY & Co • Pharmaceutical preparations
Underwriting AgreementUnderwriting Agreement • February 24th, 2023 • ELI LILLY & Co • Pharmaceutical preparations
ELI LILLY AND COMPANY Underwriting AgreementUnderwriting Agreement • September 10th, 2021 • ELI LILLY & Co • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • August 21st, 2020 • ELI LILLY & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $850,000,000 in aggregate principal amount of its 2.500% Notes due 2060 (the “2060 Notes”) and $250,000,000 in aggregate principal amount of its 2.250% Notes due 2050 (the “New 2050 Notes” and, together with the 2060 Notes, the “Securities”), in each case on the terms set forth in Schedule 2 hereto. The Securities will be issued pursuant to an Indenture, dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”), between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Citibank, N.A., the original trustee), as trustee (the “Trustee”).
Underwriting AgreementUnderwriting Agreement • April 28th, 2020 • ELI LILLY & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $1,000,000,000 principal amount of its 2.250% Notes due 2050 (the “Securities”), in the terms set forth in Schedule 2 hereto. The Securities will be issued pursuant to an Indenture dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”) between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Citibank, N.A., the original trustee), as trustee (the “Trustee”).
Underwriting AgreementUnderwriting Agreement • November 6th, 2019 • ELI LILLY & Co • Pharmaceutical preparations • New York
Underwriting Agreement February 20, 2019 Deutsche Bank Securities Inc. Barclays Capital Inc. Merrill Lynch, Pierce, Fenner & Smith Incorporated Credit Suisse Securities (USA) LLC As Representatives of the several Underwriters listed in Schedule 1...Underwriting Agreement • February 21st, 2019 • Lilly Eli & Co • Pharmaceutical preparations
Underwriting AgreementUnderwriting Agreement • May 5th, 2017 • Lilly Eli & Co • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • May 29th, 2015 • Lilly Eli & Co • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • February 26th, 2015 • Lilly Eli & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $600,000,000 principal amount of its 1.250% Notes due 2018 (the “2018 Notes”), $800,000,000 principal amount of its 2.750% Notes due 2025 (the “2025 Notes”) and $800,000,000 principal amount of its 3.700% Notes due 2045 (the “2045 Notes”), in each case having the terms set forth in Schedule 2 hereto (such 2018 Notes, 2025 Notes and 2045 Notes collectively, the “Securities”). The Securities will be issued pursuant to an Indenture dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”) between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Citibank, N.A., the original trustee), as trustee (the “Trustee”).
Underwriting AgreementUnderwriting Agreement • February 24th, 2014 • Lilly Eli & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $600,000,000 principal amount of its 1.950% Notes due 2019 (the “2019 Notes”) and $400,000,000 principal amount of its 4.650% Notes due 2044 (the “2044 Notes”), in each case having the terms set forth in Schedule 2 hereto (such 2019 Notes and 2044 Notes collectively, the “Securities”). The Securities will be issued pursuant to an Indenture dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”) between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Citibank, N.A., the original trustee), as trustee (the “Trustee”).
